Concepedia

Wei Meng

WM

28

Publications

2.4K

Citations

18

H-Index

1989

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Hubei University of Science and Technology

Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Stanford University

Wei Meng is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and drug discovery.

ORCID

Top concepts

Publications per year

1989–2024

28

Publications

28

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Wei Meng, Bruce A. Ellsworth, Alexandra A. Nirschl et al. · Journal of Medicinal Chemistry · 2008 · 612 citations · Full text

, , +10

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

Song‐Ping Han, Deborah Hagan, Joseph R. Taylor et al. · Diabetes · 2008 · 416 citations · Full text

The Pinene Path to Taxanes. 6. A Concise Stereocontrolled Synthesis of Taxol

Paul A. Wender, Neil F. Badham, Simon P. Conway et al. · Journal of the American Chemical Society · 1997 · 247 citations

, , +15

Depletion of neutrophil extracellular traps in vivo results in hypersusceptibility to polymicrobial sepsis in mice

Wei Meng, Adnana Paunel‐Görgülü, Sascha Flohé et al. · Critical Care · 2012 · 198 citations · Full text

The Pinene Path to Taxanes. 5. Stereocontrolled Synthesis of a Versatile Taxane Precursor

Paul A. Wender, Neil F. Badham, Simon P. Conway et al. · Journal of the American Chemical Society · 1997 · 172 citations

, , +12

Rows per page

1–5 of 28